Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications: Out of specification test results observed in dissolution testing during long term stability study.
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, MD 21202 by Lupin Limited, Nagpur-441108, India |
| NDC | 68180-169-16 |
| Full product label | Zileuton Extended-Release Tablets, 600 mg, 120-count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD 21202 by Lupin Limited, Nagpur-441108, India, NDC 68180-169-16 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed to 10 wholesalers/distributors and one mail order account who may have further distributed the product nationwide. |
| Quantity | 3,216 bottles |
| Recall initiated | 2022-06-10 |
| Report date | 2022-06-22 |
| Recall completed | 2023-02-08 |
| Recall number | D-1150-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗